These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 12447903

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity.
    Lescar J, Stouracova R, Riottot MM, Chitarra V, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA.
    Protein Sci; 1996 May; 5(5):966-8. PubMed ID: 8732768
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
    Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P.
    Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody.
    Rezacova P, Lescar J, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA.
    Structure; 2001 Oct; 9(10):887-95. PubMed ID: 11591344
    [Abstract] [Full Text] [Related]

  • 10. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
    Quéré L, Wenger T, Schramm HJ.
    Biochem Biophys Res Commun; 1996 Oct 14; 227(2):484-8. PubMed ID: 8967903
    [Abstract] [Full Text] [Related]

  • 11. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S, Mavromoustakos T, Chronakis N, Papadopoulos MG.
    Bioorg Med Chem; 2008 Dec 01; 16(23):9957-74. PubMed ID: 18996019
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J, Dohnálek J, Skálová T, Petroková H, Vondrácková E, Hradílek M, Konvalinka J, Soucek M, Brynda J, Fábry M, Sedlácek J, Hasek J.
    Acta Crystallogr D Biol Crystallogr; 2006 May 01; 62(Pt 5):489-97. PubMed ID: 16627941
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R, Levy Y, Tiana G.
    Curr Opin Struct Biol; 2008 Feb 01; 18(1):60-6. PubMed ID: 18160276
    [Abstract] [Full Text] [Related]

  • 18. Computational proteomics analysis of binding mechanisms and molecular signatures of the HIV-1 protease drugs.
    Verkhivker G.
    Artif Intell Med; 2009 Feb 01; 45(2-3):197-206. PubMed ID: 18926674
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.
    Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA.
    Protein Sci; 1999 Dec 01; 8(12):2686-96. PubMed ID: 10631984
    [Abstract] [Full Text] [Related]

  • 20. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.